Alto Neuroscience, Inc.
ANRODrugs in Pipeline
14
Phase 3 Programs
1
Upcoming Catalysts
3
Next Catalyst
Aug 12, 2026
4dMarket Overview
Stock performance and key metrics
3 upcoming, 2 past
ANRO Earnings Report
EPS Est: $-0.71 | FQ end 2026-06
ALTO-100 Phase 2 Est. Readout
Estimated primary completion for ALTO-100 trial (NCT06656416) in Bipolar Disorder I or II With a Major Depressive Episode. Topline data typically follows completion by weeks to months.
Source1 more catalyst beyond 14 days
Start a 48-hour free trial to see all upcoming catalysts
How ANRO's past catalysts played out
XKH004
Phase III
ALTO-100
Bipolar Disorder I or II With a Major Depressive Episode
ALTO-300 oral (PO) tablet
Major Depressive Disorder
ALTO-100 PO tablet
Major Depressive Disorder
ALTO-300 PO Tablet
Major Depressive Disorder
ALTO-300
Major Depressive Disorder
ALTO-203 25 μg
Major Depressive Disorder
ALTO-101
Schizophrenia
PA9159 Metered-Dose Inhaler, 60 μg per day for 28 days
Bronchial Asthma
PA1010
Chronic HBV Infection
PA9159 Metered-Dose Inhaler, 120 μg per day for 28 days
Bronchial Asthma
PA9159 nasal spray solution, 10 μg once daily for 14 days
Allergic Rhinitis
GB001 recombinant peptide spray low dose group、high dose group
Healthy
ALTO-207
Treatment-resistant Depression (TRD)
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
XKH004 | Phase 3 | Phase III | - | - |
ALTO-100 | Phase 2 | Bipolar Disorder I or II With a Major Depressive Episode | - | - |
ALTO-300 oral (PO) tablet | Phase 2 | Major Depressive Disorder | - | - |
ALTO-100 PO tablet | Phase 2 | Major Depressive Disorder | - | - |
ALTO-300 PO Tablet | Phase 2 | Major Depressive Disorder | - | - |
ALTO-300 | Phase 2 | Major Depressive Disorder | - | - |
ALTO-203 25 μg | Phase 2 | Major Depressive Disorder | - | - |
ALTO-101 | Phase 2 | Schizophrenia | - | - |
PA9159 Metered-Dose Inhaler, 60 μg per day for 28 days | Phase 2 | Bronchial Asthma | - | - |
PA1010 | Phase 2 | Chronic HBV Infection | - | - |
PA9159 Metered-Dose Inhaler, 120 μg per day for 28 days | Phase 2 | Bronchial Asthma | - | - |
PA9159 nasal spray solution, 10 μg once daily for 14 days | Phase 2 | Allergic Rhinitis | - | - |
GB001 recombinant peptide spray low dose group、high dose group | Phase 2 | Healthy | - | - |
ALTO-207 | Phase 2 | Treatment-resistant Depression (TRD) | - | - |
Diffuse Large B-cell Lymphoma
1 drug in this indication
Major Depressive Disorder
1 drug in this indication
Advanced Solid Tumor
1 drug in this indication
Gastrointestinal Cancer
1 drug in this indication
HCC - Hepatocellular Carcinoma
1 drug in this indication
HER2-positive Breast Cancer
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Alto Neuroscience, Inc.'s drug pipeline?→
CatalystAlert tracks 14 drug candidates in Alto Neuroscience, Inc.'s (ANRO) pipeline across Phase 3, Phase 2. Its lead program is XKH004 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Alto Neuroscience, Inc.'s next FDA catalyst?→
Alto Neuroscience, Inc.'s (ANRO) next tracked catalyst is a Earnings expected August 12, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track ANRO biotech catalysts?→
Add ANRO to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Alto Neuroscience, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.